15 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 15 of 15 clinical reviews.
Saxenda (liraglutide 3 mg) is being studied off-label for alcohol use disorder. Learn what the current clinical evidence shows, how GLP-1 receptors affect alcohol craving, what monitoring is required, and how this compares to FDA-approved AUD treatments.
Can liraglutide 3 mg (Saxenda) treat alcohol use disorder? We review the preclinical and early clinical evidence, FDA-approved indications, risks, and what patients should know about this off-label use.
A clinician-reviewed guide to the off-label use of Saxenda (liraglutide 3 mg) for alcohol use disorder, covering the current evidence base, GRADE rating, proposed dosing protocols, risks, and how it compares to FDA-approved treatments.
Liraglutide 3 mg (Saxenda) is being studied off-label for alcohol use disorder. This evidence summary covers preclinical data, early clinical trials, mechanism of action, and what clinicians should know.
Can liraglutide 3 mg (Saxenda) treat binge eating disorder? Review of clinical trials, dosing, off-label evidence, and what the research actually shows about GLP-1 receptor agonists for BED.
Liraglutide 3 mg (Saxenda) is used off-label for binge eating disorder. Review the clinical evidence, required monitoring labs, safety signals, and how prescribers manage BED patients on GLP-1 therapy.
Liraglutide 3 mg (Saxenda) is sometimes used off-label for binge eating disorder. This article reviews the evidence, dosing protocol, safety considerations, and how it compares to FDA-approved BED treatments.
Can Saxenda (liraglutide 3 mg) treat binge eating disorder? Review the off-label evidence, clinical trial data, risks, and how GLP-1 receptor agonists affect binge eating behavior.
Liraglutide 3 mg (Saxenda) is used off-label for NASH. Review the dosing protocol, LEAN trial evidence, histological outcomes, and practical clinical considerations.
A clinical evidence summary of liraglutide 3 mg (Saxenda) used off-label for nonalcoholic steatohepatitis (NASH), covering trial data, mechanisms, dosing, and guideline positions.
Liraglutide 3 mg (Saxenda) is used off-label for nonalcoholic steatohepatitis (NASH). Review the clinical trial data, monitoring protocols, liver enzyme tracking, and imaging benchmarks that guide safe prescribing.
A clinical evidence summary of Saxenda (liraglutide 3 mg) used off-label for polycystic ovary syndrome (PCOS), covering trial data, hormonal outcomes, weight effects, and prescribing considerations.
A clinical review of liraglutide 3 mg (Saxenda) used off-label for polycystic ovary syndrome (PCOS), covering trial data, metabolic and reproductive outcomes, side effects, and when prescribers consider it.
A clinical review of liraglutide 3 mg (Saxenda) used off-label for polycystic ovary syndrome (PCOS): evidence grading, dosing protocols, expected outcomes, and who may benefit most.
Liraglutide 3 mg (Saxenda) is used off-label for polycystic ovary syndrome (PCOS). Learn the evidence, monitoring protocols, and what clinicians track during treatment.